HDL-Raising Drugs: No Value in the Statin Era?HDL-Raising Drugs: No Value in the Statin Era?

In the era of widespread statin use, investigators say studies testing fibrates, niacin, and CETP inhibitors do not support raising HDL pharmacologically to reduce clinical outcomes. Heartwire
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news

Related Links:

Abstract Familial chylomicronemia syndrome (FCS) is a rare lipid disorder posing significant clinical burdens on patients. Due to its rarity, variety of presentations, and lack of universal diagnostic criteria, patients see an average of five physicians before diagnosis. We screened adults for a triglyceride level ≥1000 mg/dL from September 2015 to September 2016 and a history of pancreatitis and performed a thorough chart review on those who met the criteria. An adjudication panel used a definition that also called for supportive information including history of hypertriglyceridemia or family history of p...
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Tags: Proc (Bayl Univ Med Cent) Source Type: research
Authors: Jiang L, Wang LY, Cheng XS Abstract Familial hypercholesterolemia (FH) is an autosomal-dominant disorder that is characterized by high plasma low-density lipoprotein cholesterol (LDL-c) levels and an increased risk of cardiovascular disease. Despite the use of high-dose statins and the recent addition of proprotein convertase subtilisin/kexin type 9 inhibitors as a treatment option, many patients with homozygous FH fail to achieve optimal reductions of LDL-c levels. Gene therapy has become one of the most promising research directions for contemporary life sciences and is a potential treatment option for F...
Source: Journal of Atherosclerosis and Thrombosis - Category: Cardiology Tags: J Atheroscler Thromb Source Type: research
Conclusions: We showed that MetS is a strong risk factor for CI-AKI in nondiabetic patients undergoing elective coronary interventions; and the I-dose/CrCl ratio is a strong predictor of CI-AKI in these patients. We suggest that clinicians identify MetS patients and calculate their I-dose/CrCl ratio before coronary interventions.Cardiorenal Med 2018;8:217 –227
Source: Cardiorenal Medicine - Category: Urology & Nephrology Source Type: research
AbstractBarrett ’s esophagus (BE) is a very common condition. We have obtained fairly profound knowledge of the natural history of this condition. This results from many cross-sectional and cohort studies, many describing patients undergoing long-term surveillance. Their consent to use their clinical data has imp roved our knowledge to the benefit of these same and other patients. The prevalence of BE increases with age both in men and in women. This increase starts at a younger age in men than in women. The incidence of high-grade dysplasia and cancer in BE depends on segment length, gender, and age. The la tter two...
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
Statins are widely used to treat hypercholesterolaemia. They inhibit hydroxymethylglutaryl coenzyme A reductase (HMGCR) which is the rate-limiting step in the synthesis of mevalonate, a precursor for the biosynthesis of cholesterol (Fig. 1). In addition to their role in controlling cholesterol, there is also a solid scientific rationale to consider repurposing statins for use as anti-cancer agents[1]. Mevalonate also is a precursor for the isoprenoids farnesol and geranylgeraniol which are used to post-translationally modify several small GTPase oncogenes (e.g.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Controversy Source Type: research
The authors generally concur with Dr. Vos and Dr. Biron [1] that long-term low cholesterol levels caused by long-term statin use might be a concern, when overall mortality or survival, is an end-point, since many prospective cohort studies have shown that a low cholesterol levels was associated with higher mortality [2 –4], and the effects of the long-term cholesterol lowering treatment have not been sufficiently investigated [5]. Clinical trials, mainly performed in men with a high risk of heart disease, have showed that statin therapy reduces all-cause mortality, almost entirely by reducing heart disease morta lity...
Source: Atherosclerosis - Category: Cardiology Authors: Tags: Correspondence Source Type: research
Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts. Biogerontology. 2018 Jun 15;: Authors: Bikkul MU, Clements CS, Godwin LS, Goldberg MW, Kill IR, Bridger JM Abstract Hutchinson-Gilford progeria syndrome (HGPS) is a rare and fatal premature ageing disease in children. HGPS is one of several progeroid syndromes caused by mutations in the LMNA gene encoding the nuclear structural proteins lamins A and C. In classic HGPS the mutation G608G leads to the formation of a toxic lamin A...
Source: Biogerontology - Category: Geriatrics Authors: Tags: Biogerontology Source Type: research
The benefit of statins has been well established in reducing morbidities and mortality after carotid endarterectomy. However, the potential advantage of statin use in patients undergoing carotid artery stenting (CAS) remains largely unknown. The purpose of this study was to evaluate the effect of statins on postoperative outcomes after CAS.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Tags: Clinical paper Source Type: research
THURSDAY, June 14, 2018 -- African-Americans are less likely than whites to be treated with statins or to receive a statin at guideline-recommended intensity, according to a study published online June 13 in JAMA Cardiology. Michael G. Nanna, M.D.,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Title: Why Are Statins Underused With Black Patients?Category: Health NewsCreated: 6/13/2018 12:00:00 AMLast Editorial Review: 6/14/2018 12:00:00 AM
Source: MedicineNet Cholesterol General - Category: Cardiology Source Type: news
More News: Cardiology | Cholesterol | Heart | Niacin | Niaspan | Statin Therapy | Study